JBIO Aerovate Therapeutics, Inc.

Nasdaq aerovatetx.com


$ 9.80 $ -0.12 (-1.16 %)    

Thursday, 16-Oct-2025 15:59:47 EDT
QQQ $ 598.23 $ -2.23 (-0.37 %)
DIA $ 458.84 $ -3.15 (-0.68 %)
SPY $ 658.90 $ -4.53 (-0.68 %)
TLT $ 91.49 $ 0.68 (0.75 %)
GLD $ 401.79 $ 9.06 (2.34 %)
$ 9.785
$ 9.88
$ 6.80 x 105
$ 10.42 x 25
$ 9.68 - $ 10.37
$ 6.57 - $ 13.50
156,093
na
319.25M
$ 0.84
nm
TBD
na
na ($ 0.25)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-13-2025 06-30-2025 10-Q
2 04-25-2025 03-31-2025 10-Q
3 03-27-2025 12-31-2024 10-K
4 11-12-2024 09-30-2024 10-Q
5 08-12-2024 06-30-2024 10-Q
6 05-13-2024 03-31-2024 10-Q
7 03-25-2024 12-31-2023 10-K
8 11-13-2023 09-30-2023 10-Q
9 08-14-2023 06-30-2023 10-Q
10 05-15-2023 03-31-2023 10-Q
11 03-29-2023 12-31-2022 10-K
12 11-14-2022 09-30-2022 10-Q
13 08-15-2022 06-30-2022 10-Q
14 05-16-2022 03-31-2022 10-Q
15 03-30-2022 12-31-2021 10-K
16 11-15-2021 09-30-2021 10-Q
17 08-16-2021 06-30-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

BTIG analyst Julian Harrison initiates coverage on Jade Biosciences (NASDAQ:JBIO) with a Buy rating and announces Price Targ...

Core News & Articles

Pursuant to the terms of the securities purchase agreement, Jade is selling an aggregate of (i) 13,368,164 shares of its common...

Core News & Articles

Jade Biosciences, Inc. ("the Company" or "Jade"), (NASDAQ:JBIO), a clinical-stage biotechnology company focused...

Core News & Articles

Wedbush analyst Laura Chico maintains Jade Biosciences (NASDAQ:JBIO) with a Outperform and raises the price target from $17 ...

Core News & Articles

Guggenheim analyst Vamil Divan upgrades Jade Biosciences (NASDAQ:JBIO) from Neutral to Buy and announces $14 price target.

Core News & Articles

Preclinical data highlighted JADE101's femtomolar APRIL binding affinity, extended non-human primate half-life of approxima...

Core News & Articles

Wedbush analyst Laura Chico reiterates Jade Biosciences (NASDAQ:JBIO) with a Outperform and maintains $17 price target.

Core News & Articles

Jade Biosciences (NASDAQ:JBIO) reported quarterly losses of $(12.10) per share which missed the analyst consensus estimate of $...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION